Via Therapeutics, LLC

Via Therapeutics, LLC, based in Austin, Texas, is a small biotech firm developing novel pharmaceutical delivery technologies through federal research grants and a single-contract SBIR Phase II award from the National Institutes of Health, operating exclusively as a prime recipient with no subcontractor footprint. The company holds no SBA set-aside designations and competes in full-and-open federal grant competitions.

Via Therapeutics' core capability centers on proprietary thin-film freeze-drying technology applied to immunotherapeutics, infectious disease treatments, and whole-blood preservation. The firm is developing inhalable dry-powder formulations of combination antibiotics for non-tuberculous mycobacterial infection, microneedle-based mRNA flu vaccines for transcutaneous immunization, aerosolizable mycobacteriophage powders for tuberculosis therapy, and dried whole-blood powders for military and civilian trauma medicine. Recent federal work includes a $1.47 million SBIR Phase II definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) running through September 2026, and four NIH grant awards from fiscal 2024 through 2026: a $314 thousand Project Grant from NIAID for inhaled azithromycin-amikacin combination powders (CFDA 93.855, awarded September 2025), a $314 thousand Phase 1 STTR project grant from NIAID for the mRNA flu vaccine (awarded September 2025), a $315 thousand Phase 1 SBIR project grant from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837, awarded September 2026) for whole-blood thin-film freeze-drying, and an earlier Project Grant from NIAID for inhalable mycobacteriophage powders (awarded August 2024).

Customer concentration is near-complete with the National Institute of Allergy and Infectious Diseases; NIAID issued 7 of 11 total awards carrying the full $5.4 million combined potential value across the vendor's award footprint. The National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases account for the remaining four awards. All work is grant or SBIR contract funding from HHS-NIH institutes; no defense or civilian agency work appears in the recent footprint. Activity is modest and episodic — one award in 2023, one in 2024, and two in 2025 — with three awards reaching completion inside the next twenty-four months. SCI-reported invoicing totaled $2 million across FY2023–FY2025 (with no SCI activity in FY2022), reflecting 2.6 FTEs in FY2023, declining to 0.6 FTEs in FY2025. Government-paid hourly rates on SCI-reportable service contracts ran a median of $188.63 per hour, with senior labor at the 90th percentile pricing through $276.61 per hour. The vendor performs work exclusively in-house; no subcontractors are named across the award portfolio or SCI records.